The phase II study conducted by Andrea Cercek et al. enrolled 36 patients with MMR-deficient stage II or III rectal adenocarcinoma, who received single-agent DOSTARLIMAB, a PD-1 inhibitor, every 3 weeks for 6 months. The gene discussed is MRC1; the disease is rectum adenocarcinoma.